Effect of 16-weeks vitamin D replacement on calcium-phosphate homeostasis in overweight and obese adults. Issue 186 (February 2019)

• Record Type: Journal Article
• Authors: Mesinovic, Jakub; Mousa, Aya; Wilson, Kirsty; Scragg, Robert; Plebanski, Magdalena; de Courten, Maximilian; Scott, David; Naderpoor, Negar; de Courten, Barbora
• Is Part Of: Journal of steroid biochemistry and molecular biology. Issue 186(2019)
• Page Start: 169
• Page End: 175
• Publication Date: 2019-02
• Subjects: Vitamin D supplementation -- Calcium-phosphate homeostasis -- Overweight and obese adults -- Vitamin D deficiency -- FGF23 -- Bone mineral density; Steroid hormones -- Periodicals; Biochemistry -- Periodicals; Hormones -- Periodicals; Molecular Biology -- Periodicals; Hormones stéroïdes -- Périodiques; Steroid hormones; Periodicals; 572.579
• DOI: 10.1016/j.jsbmb.2018.10.011
• Languages: English
• ISSNs: 0960-0760

Abstract

Highlights: High-dose cholecalciferol supplementation increases 25-hydroxyvitamin D and decreases parathyroid hormone concentrations. Cholecalciferol supplementation has no effect on serum calcium, phosphate and FGF-23 concentrations. Change in parathyroid hormone is correlated with change in FGF-23 in response to 16 weeks cholecalciferol supplementation. Abstract: This randomised placebo-controlled trial aimed to determine the effect of 16-weeks cholecalciferol supplementation on calcium-phosphate homeostasis and bone mineral density (BMD) in overweight and obese adults. Fifty-four vitamin D-deficient (25OHD< 50 nmol/L), overweight and obese adults (mean age 32 ± 8.5 years) were included in the trial. Participants were randomly assigned to receive either a bolus oral dose of 100, 000 IU cholecalciferol followed by 4000 IU cholecalciferol/d or a matching placebo for 16 weeks. Before and after the intervention, serum calcium, phosphate, 25-hydroxyvitamin D [25(OH)D], intact parathyroid hormone (iPTH) and C-terminal plasma fibroblast growth factor-23 (cFGF-23) concentrations were measured. Whole-body BMD was assessed using dual-energy X-ray absorptiometry (DXA) and diet and sun exposure were assessed using self-administered questionnaires. There were no significant differences in baseline characteristics between the vitamin D and placebo group. After 16-weeks of vitamin D supplementation, mean changes in 25(OH)D concentration were higher in the vitamin D group (57 nmol/L 95% CI 49, 65) compared with placebo (2 nmol/L 95% CI -4, 8), P < 0.001. Additionally, iPTH concentrations declined in the vitamin D group (−1.19 pmol/L 95% CI −1.9, −0.47) compared with placebo (0.14 pmol/L 95% CI −0.49, 0.77), P = 0.006. There were no significant differences in calcium, phosphate, iPTH and cFGF-23 concentrations and whole-body BMD between vitamin D and placebo at follow-up. Inverse correlations were observed between mean change in serum iPTH and cFGF-23 in the vitamin D group only (r=-0.41, P = 0.029). In individuals with greater vitamin D deficiency at baseline (25(OH)D < 30 nmol/L), there was a significant increase in mean whole-body BMD (0.01 g/cm 2, 95% CI 0.001, 0.025) however, the mean change in BMD was not different between vitamin D and placebo groups in this sub-group analysis. We conclude that cholecalciferol supplementation for 16 weeks increases serum 25(OH)D concentrations and reduces iPTH concentrations in overweight and obese, but otherwise healthy adults with vitamin D deficiency, and has no effect on calcium, phosphate and iFGF-23 concentrations and whole-body BMD.